We’re improving your experience!

×

Starting April 21, you’ll be asked to log in or sign up for a free account after viewing 10 content pages each month.

Don’t worry—creating an account is quick and easy, and it comes with added benefits! Once logged in, you’ll not only continue accessing the content you already enjoy, but you’ll also unlock exclusive features like interactive donut plots for variant protein effects and variant impacts across the gene.

Stay tuned for these updates, and thank you for being part of our community!

Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT02719613
Title Continuing Treatment for Subjects Who Have Participated in a Prior Protocol Investigating Elotuzumab
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Bristol-Myers Squibb
Indications
Therapies
Age Groups: senior | adult
Covered Countries USA | TUR | ROU | POL | ITA | HUN | GRC | GBR | ESP | CAN | BEL | AUS

Facility Status City State Zip Country Details
Local Institution - 0020 Tucson Arizona 85715 United States Details
Local Institution - 0017 Bakersfield California 93309 United States Details
Local Institution - 0022 Fountain Valley California 92708 United States Details
Local Institution - 0016 West Hollywood California 90069 United States Details
Local Institution - 0019 Denver Colorado 80218 United States Details
Local Institution - 0021 Jacksonville Florida 32256 United States Details
Local Institution - 0042 Saint Petersburg Florida 33705 United States Details
Local Institution - 0009 Atlanta Georgia 30322 United States Details
Local Institution - 0003 Indianapolis Indiana 46260 United States Details
Local Institution - 0002 Boston Massachusetts 02215 United States Details
Local Institution - 0008 Saint Louis Missouri 63110 United States Details
Local Institution - 0004 New York New York 10029 United States Details
Local Institution - 0001 Bethlehem Pennsylvania 18015 United States Details
Local Institution - 0018 Dallas Texas 75231 United States Details
Local Institution - 0034 Heidelberg Victoria 3084 Australia Details
Local Institution - 0023 Antwerpen 2060 Belgium Details
Local Institution - 0011 Toronto Ontario M5G 2M9 Canada Details
Local Institution - 0010 Halifax B3H 2Y9 Canada Details
Local Institution - 0035 Athens 11528 Greece Details
Local Institution - 0036 Budapest 1097 Hungary Details
Local Institution - 0015 Ancona 60126 Italy Details
Local Institution - 0012 Firenze 50134 Italy Details
Local Institution - 0013 Genova 16132 Italy Details
Local Institution - 0043 Ravenna 48121 Italy Details
Local Institution - 0044 Terni 05100 Italy Details
Local Institution - 0014 Torino 10126 Italy Details
Local Institution - 0046 Aomori-shi Aomori 0308553 Japan Details
Local Institution - 0047 Shibukawa-shi Gunma 3770280 Japan Details
Local Institution - 0049 Osaka-shi Osaka 5300012 Japan Details
Local Institution - 0048 Koto-ku Tokyo 135-8550 Japan Details
Local Institution - 0050 Chiba 260-8677 Japan Details
Local Institution - 0045 Kasama-shi 3091793 Japan Details
Local Institution - 0027 Chorzow 41-500 Poland Details
Local Institution - 0026 Warszawa 02-106 Poland Details
Local Institution - 0039 Warszawa 02-776 Poland Details
Local Institution - 0028 Bucuresti 030171 Romania Details
Local Institution - 0029 Iasi 700483 Romania Details
Local Institution - 0041 Barcelona 08036 Spain Details
Local Institution - 0030 Toledo 45004 Spain Details
Local Institution - 0031 Cebeci Ankara 06620 Turkey Details
Local Institution - 0032 London EC1A 7BE United Kingdom Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field